Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

NCT04375813 is registered in ClinicalTrials.gov with Robert Svatek as lead sponsor.

NCT NCT04375813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Lead sponsor
Robert Svatek
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 25, 2021
Completion date
July 31, 2027
Enrollment
166 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer